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EFFECT OF THE WHISTLE WATCH 
DEVICE ON BRONCHODILAT OR 
USE IN CHILDREN WITH ASTHMA 
K Savva, E U Rosen, K D Bolton, 0 Thein, Z Mayet 
Objective. To determine if the use of the whistle watch 
ryYW), a simple device to monitor peak flow rate, affects the 
use of bronchodilators at home. 
Study design. Prospective, randomised, crossover design. 
Setting. The asthma outpatients' clinic at Coronation 
Hospital, a tertiary care centre in Johannesburg. 
Patients and methods. Children between 6 and 18 years of age 
with moderate or severe asthma for more than a year were 
enrolled. They were randomised into two groups, with 
bronchodilator use determined either by the WW or solely 
by the patient's perceived symptomatology. The patients 
acted as their own controls, switching over to the other 
group after 30 days. Eighty patients were enrolled into the 
study. 
Results . Forty-three patients completed the study (54%). 
There were no significant differences between these patients 
and those who did not complete the study in terms of sex, 
age and treatment characteristics. There was a significant 
reduction in the mean monthly number of bronchodilator 
doses used by the WW group (5.5 doses v. 16.81 doses, 
paired t-test, t = 3.64, P < 0.001, 95% confidence interval (CI) 
6.1 - 16.55). The change in individual participants varied 
between 13 extra bronchodilator doses and 71 fewer doses 
per month ·with the use of the WW device. 
Conclusion. The WW device is a cheap, easy-to-use and 
effective tool that reduces the number of bronchodilator 
doses used by asthmatic children at home. 
5 Afr Med /20!Jl; 91: 234-237. 
Effective management of childhood asthma consists of a 
combination of appropria te drug therapy, education of 
caregivers, and home monitoring of peak expiratory flow rate. ' 
The latter is of special importance as asthma sufferers are often 
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unaware of their need for bronchodilator therapy. Studies have 
shown that patients can monitor their own peak flow reliably 
by using portable peak flow meters.' 
Peak flow meters, however, have some disadvantages. They 
can be inaccurate and they are based on an effort-dependent 
manoeuvre. The patient must be numeral literate to be able to 
measure the peak flow and to compare it with the best 
predicted value. In addition, the portable peak flow meters are 
relatively expensive (present cost approximately R90 - R200)/ 
and are not child-friendly. 
The whistle watch ryYW), first introduced in 1998,' is an 
alternative device. It has many advantages. It is much cheaper 
(R21.50- State hospital price), its accuracy has been 
established,' it is pocket-sized, and it is lighter than other peak 
flow meters. It is also a child-friendly device and its whistling 
tone encourages the co-operation of children, which results in 
greater expiratory effort by them. The device operates through 
a threshold-activated whistle to register peak flow. This 
threshold can be adjusted from 130 to 340 1/ min, in steps of 
101 / min, by varying the size of the vent opening.' The lifespan 
of the device is at least 2 years. 
As the WW appears to offer an objectiv~ way for the patient 
and the caregiver to monitor lung function at home, this study 
was undertaken to establish how the use of the WW would 
affect the frequency of bronchodilator use at home when 
compared with bronchodilator use based on symptomatology 
only. 
M ETHO DS 
Subjects 
Eighty asthmatic children were recruited from the paediatric 
asthma outpatient clinic at Coronation Hospital between 
February and September 1999. Coronation Hospital is a 
teaching hospital affiliated to the Department of Paediatrics of 
the University of the Witwatersrand and situated in 
Johannesburg, an urban environment. 
Inclusion criteria 
Participants had to be between 6 and 18 years of age. They had 
to have a diagnosis of moderate asthma (symptoms such as 
cough, wheezing, etc. occurring up to once per week) or severe 
asthma (symptoms occurring more than once per week), 
requiring daily anti-inflammatory (inhaled steroid) therapy as 
well as the intermittent use of inhaled ~-agonists. In addition, 
the children needed to be taller than 111 em (a criterion for the 
effective use of the WW), not using conventional peak flow 
meters, and to have a history of good therapeutic compliance. 
Exclusion criteria 
We excluded patients with newly diagnosed asthma (diagnosis 
made less than a year before the study), any case in which the 
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diagnosis of asthma was uncertain, patients with other causes 
of wheezing (e.g. cardiac illness, known immune deficiency, 
known metabolic disease, confirmed gastro-oesophageal 
reflux), those with mental retardation, and cases where consent 
was refused. 
Study design 
The study used a randomised, crossover design with subjects 
acting as their own controls. Block randomisation was used. 
Patients were randomised to either group A, who used the WW 
to determine their need for bronchodilators (therapeutic 
regimen 1), or to group B, who used bronchodilators at their 
own discretion (therapeutic regimen 2). After a 30-day period, 
the patients switched over from regimen 1 to regimen 2 for 
another 30 days. 
Description of the study groups 
In group A, the WW group (therapeutic regimen 1), the 
children received instructions regarding the use of the WW. 
The threshold was set by the investigators at 80% of the 
patient's best peak expiratory flow rate. They were instructed 
to use the WW twice daily (morning and evening) and to 
record on charts whether they succeeded or failed to obtain an 
audible whistle. If a whistle was elicited there was no need for 
bronchodilators, and vice versa. Use of bronchodilators was 
also allowed in the event of asthma symptoms developing, or 
pre-exercise. Participants had to keep records of this. 
In group B (therapeutic regimen 2), participants were 
instructed to use bronchodilators as needed. This is usually 
based on the occurrence of asthma symptoms (.breathlessness, 
wheezing, cough, etc.). They, too, kept records of their use of 
bronchodila tors. 
Study visits 
The study period lasted for 60 days and the children were seen 
monthly. 
During visit 1 (randomisation), eligible subjects were 
identified and randornised. Appropriate charts along with the 
WW (for therapeutic regimen 1) and user instructions were 
provided. 
During visit 2, 30 days_ later, patient charts were checked. If 
the patients had followed the instructions correctly (100% 
recording on charts of bronchodilators and/ or WW use), they 
switched from therapeutic regimen 1 to therapeutic regimen 2, 
and vice versa. The next appointment was booked for 30 days 
later. In cases where the patients had failed to follow 
instructions they were asked to continue with the same 
therapeutic regimen for another 30 days. Participants who 
failed to comply with the study instructions after two attempts 
were excluded from the study. 
During visit 3 participant charts were reviewed. Those who 
had incorrectly /incompletely filled in charts were asked to 
repeat the same process for another 30 days. 
Visit 4 was a final visit for chart retrieval. 
Sample size calculation 
In calculating the sample size, a difference in the frequency of 
the use of bronchodilators of 10% between the two groups was 
considered to be clinically significant. Assuming that the 
frequency of bronchodilator use would vary from zero to three 
times a day, a m.iniJ:p.um sample size of 32 patients in each 
group was required for statistical_ significance at a 5% level of 
significance and a power of 90%. 
Statistical analysis 
Statistical significance testing for the effect of the WW on the 
number of doses of bronchodilators was done using the paired 
t-test. Groups were compared using the Z-test. A P-value of 
< 0.05 was considered to be statistically significant. 
This was an investigator-initiated study. The WWs were 
provided free by HarMed and Boehringer Ingelheirn. o other 
funds were obtained from these companies or other sources. 
Ethical clearance for the study was obtained from the 
Committee for Research on Human Subjects of the University 
of the Witwatersrand. 
R ES ULTS 
Dropouts 
Thirty-seven patients (46%) were excluded from the analysis of 
the study; of these, 18 (49%) had incomplete charts. Eight 
patients were excluded after the first review of the charts 
(22%), and the remaining 10 after a second review (27%). 
ineteen patients failed to return after enrolment in the study 
(24%). There was no significant difference between these 37 
patients and those in the final analysis with regard to age, sex, 
parental education level, race, usual mode of transport, type of 
bronchodilator used, steroid use and randomisation groups. 
Subjects 
Forty-three children were included in the final analysis of the 
study. The mean age was 10.7 years (range 6.8- 16.4 years, 
standard deviation (SD) ± 2.44). Twenty-three of the children 
(53%) were male. The mean height was 141 em (range 118.5-
168.0). Twenty-one patients were on budesonide (Inflamrnide), 
19 on fluticasone (Flixotide) and 3 on beclometasone (Becotide). 
Fenoterol (Berotec) was used by 28 participants, and 15 used 
salbutamol (Ventolin) as their bronchodilators. Twenty-two 
subjects (51%) were initially allocated to group Band the rest 
(49%) to group A. Information regarding ethnicity was 
available in 42 cases: 33 were coloured, 5 black and 3 Indian 
and 1 was white. The primary caregiver's level of education 
__ _,., 
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was available in 34 cases: 1 parent had tertiary education, the 
educational level of 28 varied from Grade 9 to Grade 10, and in 
5 others it was Grade 8 or less. Three subjects walked to the 
clinic, 9 children used family transport and 29 relied on public 
transport (information was unavailable in 2 cases). 
Bronchodilator usage 
Bronchodilators were used significantly less in the WW group. 
The mean number of bronchodilator doses used per month was 
5 .46 ± 8.13 for group A, versus 16.81 ± 19.99_ for group B 
(difference in mean= 11.33, t = 3.64, P < 0.001, df = 42) (Table I, 
Fig. 1). Ten cases showed an increase in bronchodilator doses 
used during the WW-usage period, and 33 cases (77%) used 
bronchodilators more during the phase of self-monitoring of 
symptoms (group B). Of the 43 patients, only 4 were using 
bronchodilators before exercise. o· data were collected on how 
often participants were exercising. 
Table I. Frequency of the use of short-acting bronchodilators per 
month 
Paired 
Group Mean§ Median Range SD t-test P-value 
Group A 5.46 0-31 8.13 
Group Bt 16.8 11 0-80 19.99 
A- Bl 11.33 20.38 3.64 < 0.001 
• Group A= whistle watch group. 
+ Group B = self-monitoring. 
t Difference in the number of bronchodilator doses used between the two groups. 
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Fig. !· D_ifferences in the use of short-acting bronchodilators by 
paedzatnc subjects. Therapeutzc regzmen 1: use of the whistle watch 
therapeutic regimen 2: self-monitoring group. ' 
DISCUSSIO N 
An accurate assessment of the severity of asthma is crucial for 
optimal management. This study found that paediatric subjects 
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with moderate to severe asthma required 67% less 
bronchodilator use with the aid of the WW device compared 
with the amount used during self-monitoring, confirming the 
usefulness of the WW device. However, does less 
bronchodilator use by WW users correspond with better 
asthma management? The study cannot clearly answer this 
question. There were no acute asthma exacerbations requiring 
emergency care visits in either group. Therefore, the inference 
is that many asthmatic children and their parents/ caregivers 
attribute many symptoms unnecessarily to asthma 
exacerbation and ignore other considerations or diagnoses 
(such as coryza, allergic rhinitis, sinusitis, etc. ). 
It is well established that children and/or their caregivers 
demonstrate considerable variation in the extent to which their 
subjective evaluations correspond with objective measures of 
airway obstruction.;.~• Peak expiratory flow rate meters offer 
one such objective measure of pulmonary function which can 
enhance home self-management of asthma, including the more 
appropriate use of bronchodilators. Unfortunately, they are 
relatively expensive and may be inaccurat~. 11-15 Studies have 
also shown that there is poor utilisation of these devices by 
families ·with asthmatic children (as few as 30% of families in 
one study).16"17 
The WW offers an attractive altemative. It is much cheaper 
(costing R21.50), its accuracy has been established; it is pocket-
sized, and it is lighter than other peak flow meters. It is also a 
child-friendly device and its whistling tone encourages the co-
operation of children, which results in greater expiratory effort 
by them.' 
The cost savings that may be attained by the use of the 
device may also be substantial. Considering that use of the 
WW may save a mean of 11.3 bronchodilator doses monthly, 
this extrapolates to a saving of about R4.20- R48.50 (depending 
on the bronchodilator used -State hospital prices) annually. 
This should be contrasted with the once-off cost of the WW 
device (R21.50). The lifespan of the device is at least 2 years. 
The major limitation of this study is the high dropout rate. 
This is explained by two main factors. First, the requirement for 
absolute compliance with the study protocol (i.e. recording all 
bronchodilator use and/ or WW readings), which should be an 
integral part of routine asthma monitoring and care, resulted in 
almost half of all dropouts. This highlights the fact that 
asthmatic patients often have poor understanding of their 
condition and fail to pay attention to detail in the management 
of this condition. Second, the poor socio-economic situation of 
patients (as evidenced by reliance on public transport, poor 
caregiver education levels, etc.) was the other major reason for 
dropouts. In these circumstances it is expected that the level of 
therapeutic inconstancy will also be high, and that perhaps the 
WW may motivate better compliance, particularly if combined 
with more appropriate and better-directed education. The 
results reaffirm the importance of more time being spent on 
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educating the children and their families about optimal asthma 
managemen t. 
Use of pre-exercise prophylaxis was low in this cohort. Only 
4 patients (9%) were using bronchodilators before exercising. 
None of them was on a long-acting bronchodilator (Serevent), 
which may eliminate the need for exercise prophylaxis. Of the 
remaining 39 participants, 8 were on Serevent. While this 
pattern of pre-exercise bronchodilator use suggests a 
prevalence of 9 - 28% of exercise-induced asthma in this cohort, 
this figure is low compared with figures from other studies in 
which exercise-induced asthma was found to occur in up to 
90% of asthmatics. 18 Indeed, on reviewing the records of 69 of 
the 80 patients enrolled in the study, as many as 52 cases (75%) 
had reported exercisecinduced cough or I and wheezing. 
In conclusion, the use of the WW decreased the utilisation of 
bronchodilators and offered a more rational approach to 
asthma management. It also provides cost benefits to a health 
service that is chronically underfunded. Furthermore, the study 
underlies the need for doctors to improve their communication 
skills with both asthmatic children and their parents. 
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A _LLERGENICITY AND CROSS-
REACTIVITY OF BUFFALO GRASS 
(STENOTA PHRUM SECUNDA TUM) 
Ru th A Prescott, Pau l C Potter 
Background. In the subtropical climate of South Africa, grasses 
of the subfamily Panicoideae are predominant. Bermuda 
grass has previously been shown to be an important local 
allergen, and immunoglobulin E (IgE) epitopes of Bermuda 
grass extracts are known to be distinct from those of the 
Pooid pollen extracts. Following our demonstration of 
sensitivity in 43% of patients grass-allergic to the Panicoid, 
Kikuyu grass, we have studied the closely related buffalo 
grass, Stenotaphrum secundatum, indigenous to the Western 
Cape region, the east coast of Africa and the oceanic islands 
such as Mauritius; and Eragrostis, another common 
indigenous grass with a wide distribution. 
Objective. To partially characterise the allergens of buffalo 
pollen, and examine its immunological relationships with 
local common grasses such as Eragrostis and Kikuyu. 
Methods. Grass-allergic patients were evaluated clinically, and 
skin prick tests (SPTs) and radio-allergosorbent tests (RASTs) 
to Bermuda and grass mix were performed. Sera of timothy 
grass-sensitive patients from Belgium were also included in 
this study. Pollen extract from buffalo grass was characterised 
by specific IgE bindirig by means of immunoblotting and 
enzyme-linked immunosorbent assay (ELISA). Cross-
reactivity between the grasses was studied by means of 
inhibition of IgE binding. 
Results. More than 90% of grass-sensitive patients were found 
to have IgE antibodies to Buffalo and Eragrostis pollen. 
Inhibition of ELISA and immunoblots revealed that extracts 
of these grass pollens could significant inhibit IgE binding to 
the local grass pollens, Kikuyu, buffalo, Eragrostis and 
Bermuda on solid phase, but 100% inhibition was never 
achieved, indicating that cross-reactive but also unique 
epitopes are present. We also identified a subset of patients 
with negative RASTs to Bermuda, and minimal inhibition by 
Bermuda pollen extract. 
Conclusion. Buffalo and Eragrostis are important aero-
allergens in the Cape, dispersed during the long dry, windy 
summer. Our data suggest that the local grasses are major 
sensitisers, and that South African diagnostic p~els should 
include extracts of buffalo and Eragrostis grasses. 
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